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KEY POINTS
• WT1 mRNA-electroporated dendritic cells can prevent or delay relapse in 43% of AML patients in remission after chemotherapy.
• OS compares favorably with the new survival data from the SALR, and correlates with molecular and WT1-specific CD8 + T-cell responses. 
ABSTRACT
Relapse is a major problem in acute myeloid leukemia (AML) and adversely impacts survival.
In this phase II study, we investigated the effect of vaccination with dendritic cells (DCs) electroporated with Wilms' tumor 1 (WT1) mRNA as post-remission treatment in 30 
INTRODUCTION
Acute myeloid leukemia (AML) still has a dismal prognosis. 1, 2 According to the latest data of the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, 1 the 5-year overall survival (OS) of AML is only around 25%. One of the major reasons for this is that the majority of patients relapse even after complete remission (CR) is achieved with standard chemotherapy. 3 Relapse is usually caused by the persistence of a small population of residual leukemic cells, a condition designated as minimal residual disease (MRD). 4 Allogeneic hematopoietic stem cell transplantation (allo-HSCT), the best established post-remission treatment to eradicate MRD, decrease the risk of relapse and increase survival following chemotherapy, is still beset by substantial morbidity and mortality. 5 As a consequence, allo-HSCT is generally not considered as a therapeutic option in the large group of older AML patients. For these patients and for younger patients without a compatible donor, there is currently no standard adjuvant treatment to prevent postchemotherapy relapse. 4 The beneficial effect of allo-HSCT against leukemia is mediated in large part by Tcells that are capable of recognizing antigens expressed on the leukemia cells and of subsequently mediating AML cell killing. 6 
Stimulation of autologous T-cells by in vivo
immunization with leukemia-associated antigens is an innovative strategy to combat relapse in AML, 7-11 acting via the reduction or eradication of MRD. Several antigens have been identified to serve as T-cell targets in AML, including the Wilms' tumor protein 1 (WT1) which is highly overexpressed in AML and is also involved in leukemogenesis. 12 In view of their role as the most potent antigen-presenting cells of the immune system, dendritic cells (DCs) are eminently equipped to stimulate antigen-specific T-cell immunity. 13 This explains the strong interest in the use of these cells for cancer vaccination strategies. 14 The aim of this phase II study was to determine the clinical efficacy of DC vaccine therapy in AML, and, more specifically, whether this form of immunotherapy can be applied in the adjuvant setting to decrease the risk of relapse following chemotherapy and to improve survival. To this end, we here vaccinated 30 AML patients in remission but at very high risk of relapse with autologous DCs loaded with the WT1 antigen by means of mRNA electroporation, a technique that allows for human leukocyte antigen (HLA) haplotypeindependent, multi-epitope antigen presentation to T-cells. 15, 16 A N  G  U  I  L  L  E  e  t  a  l  D  E  N  D  R  I  T  I  C  C  E  L  L  S  A  S  P  O  S  T  -R  E  M  I  S  S  I  O  N  T  R  E  A  T  M  E  N  T  I  N  A  M  L   6 
METHODS

Patients
Thirty AML patients were enrolled in this phase II study (ClinicalTrials.gov identifier NCT00965224), whereby the first 10 patients were also included in a preceding feasibility, safety and immunogenicity study (ClinicalTrials.gov identifier NCT00834002). 17 
DC vaccination
Clinical grade WT1 mRNA-electroporated DC (WT1/DC) vaccines were prepared and administered intradermally as described previously. 16, 17 Three different WT1 constructs were used to generate mRNA by in vitro transcription ( Figure 1 , Table S1 ): construct 1 ("WT1"), 
Molecular tumor marker monitoring and clinical response criteria
Longitudinal monitoring of WT1 transcripts was performed as described previously using an in-house assay, 17,19 the ipsogen WT1 ProfileQuant Kit (Qiagen) 20 or the WT1 mRNA
OneStep Assay (Otsuka Pharmaceutical Co). 19 WT1 mRNA levels above background (respectively above 1 and 25 copies of WT1 mRNA per 1,000 ABL copies in blood and marrow in the in-house assay; according to manufacturer's instructions in the commercial kits) are indicative of MRD and herald full relapse. [21] [22] [23] [24] [25] Responders were characterized by molecular remission (MR) or by stable disease (SD). MR was defined by normalization of WT1 mRNA levels in blood and/or bone marrow during WT1/DC vaccination, while reaching or maintaining hematological CR. SD was defined by stable WT1 blood transcript levels above background, with stable blood values without blasts. The minimum duration of SD was 2 months, after which WT1 mRNA levels did not increase by more than a factor of 0.5 log 10 and at least 1 basic blood value (hemoglobin, thrombocyte count and/or absolute neutrophil count) was normal. Patients who relapsed without achieving MR or SD status were
categorized as non-responders. The classical definitions of CR, partial remission (PR), relapse and survival were used. 26 Long-term survivors were defined as surviving for at least 3 yr 26,27 and long-term responders as patients with a MR or SD response remaining in CR for at least 3 yr, after the first dose of WT1/DCs.
Immunomonitoring
Detection and subtyping of anti-WT1 antibodies in pre-and post-vaccination plasma samples was performed as described previously. 17, 28 The increase in WT1 IgG antibody levels after vaccination was determined by subtraction of the corresponding pre-vaccination values.
Cytokine plasma levels were determined using the Th1/Th2 multiplex immunoassay (Bender MedSystems). Ex vivo flow cytometric analysis of lymphocyte subsets was performed using directly conjugated monoclonal antibodies (BD Biosciences).
Circulating WT1-specific CD8 + T-cells obtained before vaccination and after the fourth dose of WT1/DCs were stained with peptide-HLA-A*0201 tetramers and quantified as described previously. 17,29 Whenever cells were available they were also analyzed at different time points afterwards until relapse and/or progression.
Two weeks after the 4th WT1/DC vaccination, delayed-type hypersensitivity (DTH) was tested against the complete vaccine (i.e. keyhole limpet hemocyanin [KLH]-exposed WT1/DCs, except in patients UPN11, 12, 13 where non-KLH-exposed WT1/DCs were used).
This was performed by intradermal injection of 0.5 x 10 6 WT1/DCs on the back of the patient.
Forty-eight hours later, erythema and induration at the injection site were measured and skin punch biopsies were taken for culture of DTH-infiltrating lymphocytes (DILs). These DILs were allowed to expand for 2-3 weeks in medium with interleukin (IL)-2 (100 IU/mL).
Expanded DILs were then harvested and tested for antigen specificity as described previously. 17
Data mining and statistical analysis
Statistical calculations and data graphing were carried out using Prism version 5.01 (GraphPad). A P value <0.05 was considered statistically significant.
RESULTS
Patients
WT1/DC vaccination as a post-remission treatment was evaluated in 30 high-risk AML patients in remission following chemotherapy. Patient characteristics with baseline evaluation and initial treatments are shown in Table S1 . There were 15 males and 15 females, with a median age at diagnosis of 65 yr. Prior to WT1/DC vaccination, 27 patients had achieved CR following chemotherapy, whereas 3 had partial remission (PR). Six patients had a preceding hematological disorder, myelodysplastic syndrome (n=5) or myeloproliferative neoplasia (n=1). The cytogenetic risk group 30 An example of SD is shown in Figure 2 . The stable WT1 profile seen during SD contrasts with the steeply rising curve that is usually seen when AML patients are relapsing. 19, 23, 25 Only a minority of patients had a molecular MRD marker other than WT1 mRNA.
Overall, there was a corresponding evolution, between the WT1 transcript levels and other markers of MRD, such as the fusion transcripts RUNX1-RUNX1T1 (translocation t(8;21)) and (16)). For instance, in clinical responder UPN15, the
CBFB-MYH11 (inversion inv
normalization of bone marrow WT1 expression after 4 WT1/DC vaccinations (from 638 to 4 copies/1000 ABL copies) was paralleled by a decrease of RUNX1-RUNX1T1 transcript levels from 1.43 to 0.0495 copies/1000 ABL copies. In non-responder UPN28, the increase in already elevated blood WT1 transcript levels (from 24.1 to 1195 copies/1000 ABL copies) was mirrored by an increase of CBFB-MYH11 levels from 10 to 469 copies/1000 ABL copies. (Table 1) .
In contrast, 25/26 patients who were vaccinated with WT1/DCs were destined to relapse based on increased pre-vaccination WT1 transcript levels and/or relapsed. 
As shown in 
WT1/DC vaccine-induced immune responses
Immunomonitoring was performed on PBMCs, DILs and plasma samples obtained before and/or after WT1/DC vaccination. There were no significant changes after vaccination with Figure 4D ). In some long-term responders (UPN14) or survivors (UPN17, 34, 35) , the proportion of IFN-γ + and/or TNF-α + WT1-specific CD8 + DILs was very high (range 5%-50%). IFN-γ + and TNF-α + WT1-specific CD8 + , but not CD4 + DIL responses were significantly higher in patients vaccinated with the DC-LAMP-containing WT1 constructs as compared to those vaccinated with the wild type WT1 construct (data not shown).
DISCUSSION
In this phase II study, we demonstrated clinical activity of autologous WT1 mRNAelectroporated DC vaccination in patients with AML in remission and showed that this form of cancer vaccine therapy may offer overall survival (OS) benefit that is linked to the induction of WT1-specific CD8 + T-cell immunity. have been made in WT1 peptide vaccine trials in AML, 7, 8, 32 indicating that SD should be included as a separate category in the response assessment of immunotherapeutic interventions in hematological malignancies as it is now routinely the case in the field of solid tumor immunotherapy. 33 Altogether, the data above indicate that WT1-targeted DC vaccination can be an effective strategy to prevent or delay relapse in AML, without the toxicity of allo-HSCT. This is an important finding in light of the growing number of elderly AML patients who are generally not considered candidates for allo-HSCT because of toxicity considerations. 5 Based on these results, a place for WT1/DC vaccination can also be foreseen for younger AML patients who do not proceed to allo-HSCT after standard chemotherapy because of refusal or lack of a suitable donor.
The OS data in this study compared favorably with current and new data from SEER chemotherapy and/or allo-HSCT) has been reported to be 46%, 35 whereas the CR2 rate in our study was 73.3%. Likewise, the 5-yr OS rate of WT1/DC-vaccinated AML patients following first relapse was 36.8% in this study, which compares favorably to the 11% 5-yr OS rate of AML patients in first relapse that has been described in the literature. 35 These data suggest that WT1/DC vaccination can potentiate the response to subsequent treatment, providing an explanation for how vaccination contributes to prolongation of survival. A similar scenario has been reported for solid tumors, where improved clinical outcomes have been documented in patients who received chemotherapy after apparently failing immunotherapy as compared to patients who received chemotherapy alone. [36] [37] [38] [39] [40] [41] [42] [43] [44] This outcome may reflect synergism between immunotherapy and chemotherapy, the latter having not only antiproliferative but also immunostimulatory effects. 6, 13 The precise mechanisms underlying the anticancer synergy between tumor vaccines and chemotherapy are currently being investigated; 41 one potential mechanism involves the release of cytokines (such as TNF-α)
by vaccine-induced CD8+ T-cells, which in turn enhances the ability of chemotherapy to induce apoptotic tumor cell death. 45 In this study, clinical response and survival were found to be correlated with induction of WT1-reactive CD8 + T-cell immunity by the DC vaccination, providing a mechanistic basis for the anti-leukemic activity of WT1/DCs. First, we found a correlation between long-term clinical response and increased circulating frequencies of poly-epitope WT1-specific tetramer + CD8 + T-cells. The maintenance or increase of the frequencies of WT1-specific CD8 + T-cells at relapse or progression, points towards antigen-driven immune activation associated with increasing exposure to the WT1 antigen at relapse 46 and with the continuation of the WT1/DC vaccination. This suggests that antigen-specific T-cell numbers may be necessary, but not sufficient to ultimately control AML. Second, we found a correlation between WT1-specific IFN-γ + and/or TNF-α + DTH-infiltrating CD8 + T-lymphocytes and long-term OS. This suggests that CD8 + T-cell function is needed for long-term control of AML, at least in the immunotherapy setting. Since DTH was not performed in this study at the time of relapse, we cannot exclude that despite a maintenance or increase in WT1specific cell numbers, their function may be deficient at that time.
In line with preclinical data, 18 3 different WT1 constructs were used in this study: a native full-length WT1 construct, a WT1 construct incorporating the lysosomal targeting signal of DC-LAMP, and a codon-optimized version of the latter construct. Theoretically, the
DC-LAMP-containing constructs would facilitate MHC class II antigen presentation and subsequent CD4 + T-cell stimulation. Contrary to expectations, no statistical evidence for induction of WT1-specific CD4 + T-cell immunity was found in the patients in whom the DC-LAMP-containing constructs were used. This is in contrast with a recently published study in melanoma, which used DCs loaded with melanoma antigen-encoding mRNA linked to a similar DC-LAMP construct. 47 The apparent lack of CD4 + T-cell stimulation in our hands may be due to the fact that the strongly immunogenic WT1 332-347 MHC class II epitope 48, 49 is not encoded by the DC-LAMP-containing constructs because they lack the WT1 nuclear localization signal (NLS). 18 Table S1 ). 
